Authors: Sesti, G.; Hribal, M. L.

Source: Current Pharmacogenomics, Volume 4, Number 1, March 2006 , pp. 69-78(10)

Publisher: Bentham Science Publishers

Abstract:

Type 2 diabetes is a complex and heterogeneous metabolic condition that has reached epidemic proportions, affecting more than 150 million individuals worldwide. Maintenance of near-normal glucose control in patients with type 2 diabetes been shown to be associated with a reduced risk of microvascular complications as well as a trend toward reduction of macrovascular events. Treatment with antihyperglycemic agents is initially successful in type 2 diabetes, but it is often associated with a high secondary failure rate, and the addition of insulin is eventually necessary to restore acceptable glycemic control for many patients. The molecular reasons for the different responses to antidiabetic therapy are not clear, and the possibility that genetic factors may predispose to failure to respond adequately to oral antidiabetic agents remains an open question. Pharmacogenetics is an emerging discipline that involves the search for genetic polymorphisms, commonly observed among the general population, which influence drug response. Interesting candidate genes belong to three main groups: 1) genes encoding for drug metabolizing enzymes and/or transporters that influence pharmacokinetics; 2) genes encoding for targets and/or receptors of drugs that influence pharmacodynamics; and 3) genes encoding for proteins that are involved in the causal pathway of disease and are able to modify the effects of drugs. In this review, we will discuss our current understanding of genetic polymorphisms that may affect responses of patients with type 2 diabetes to antidiabetic oral treatment as well as the main challenges, which should be addressed in order to translate pharmacogenetics principles into widespread clinical practice.

Keywords: hyperglycemia; CYP2C8 genotypes; glimepiride; Thiazolidinediones (TZD); Uncoupling protein 2 (UCP2)

Document Type: Research article

Affiliations: 1: Dipartimento di Medicina Sperimentale e Clinica, Universita di Catanzaro-"Magna Graecia", Via Tommaso Campanella, 115, 88100 Catanzaro, Italy.

Publication date: 2006-03-01

More about this publication?

• Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.
  
  The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology ,  Genetics
• By this author: Sesti, G. ;  Hribal, M. L.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers